Amsterdam UMC spin-off PacingCure received EIC Transition funding

Amsterdam UMC spin-off PacingCure received a prestigious EIC Transition grant of 2.5 million euros.

PacingCure develops platform gene transfer technologies for the heart and uses these technologies to engineer novel treatments for cardiac arrhythmias in patients with high unmet medical needs. The selected indications have attractive translational aspects for developing advanced therapy medicinal products (ATMP) for patients that need them the most.

The three founders, Geert Boink, Osne Kirzner, Hanno Tan, and their co-applicant Prof. Vincent Christoffels (Amsterdam UMC), were awarded the prestigious Transition grant from the European Innovation Council (EIC) for their achievements and planned activities to develop their core technologies towards clinical implementation. The current EIC project will fund a comprehensive package of final stage pre-clinical development, align with regulatory authorities and develop an investor-ready business proposition.

About the founders
Geert Boink is a cardiologist, leading a translational research group that is embedded in the Departments of Cardiology and Medical Biology. Dr. Boink also serves as the CEO of PacingCure. Hanno Tan is a cardiologist, and Principal Investigator at the Department of Clinical and Experimental Cardiology who leads various European consortia that study the causes and develop treatments for sudden cardiac arrest. Dr. Tan serves as the CMO of PacingCure. Osne Kirzner is an anesthesiologist with experience in finance & law. This combined expertise allows him to bridge the gap between the target clinical indications and business needs, thereby facilitating valorization objectives. Osne serves as the CFO of PacingCure.

Previously, PacingCure received funding from, among others, Health Holland, the Innovatiefonds Noord Holland, the Nederlandse Wetenschappelijke Organisatie (NWO), and the European Commission.

Support by IXA
IXA has supported Pacing Cure over the years, among other things by participating in PacingCure’s advisory group and thus preparing their team for the oral defense with this grant. Business developer Marc Roelofs also played an important role in developing their business case during the Venture Challenge in 2020 (and beyond), which they also won.